Diazoxide

Overview

Diazoxide (Proglycem®) is an orally administered medication used in veterinary medicine primarily to manage hypoglycemia associated with excessive insulin secretion, particularly in dogs with insulinoma. It is considered when patients do not respond adequately to dietary modification and glucocorticoid therapy.

Diazoxide has both vasodilatory and hyperglycemic properties. While structurally related to thiazide diuretics, it does not possess clinically significant diuretic effects. Its primary clinical benefit lies in increasing blood glucose levels and reducing hypoglycemic episodes.

Mechanism of Action (MOA): Diazoxide inhibits pancreatic insulin release by decreasing intracellular calcium availability in beta cells, thereby preventing insulin secretion. It also increases blood glucose through stimulation of hepatic gluconeogenesis and glycogenolysis, and by promoting catecholamine (epinephrine) release, which reduces peripheral glucose utilization.

Indications

Diazoxide is used in dogs and cats for the management of hypoglycemia associated with excessive insulin secretion, particularly in cases where standard therapies are insufficient or not tolerated.

• Insulinoma-associated hypoglycemia: Primary indication in dogs for control of hypoglycemia caused by insulin-secreting tumors.
• Refractory hypoglycemia: Used when dietary management and glucocorticoid therapy alone fail to adequately control blood glucose levels.
• Adjunctive therapy: May be incorporated into multimodal treatment protocols to improve glycemic control and reduce frequency of hypoglycemic episodes.

Dosage (Reference)

Dog

In dogs, diazoxide is used as an adjunctive therapy for hypoglycemia associated with insulin-secreting tumors. Dosing should begin at the lower end and be gradually increased based on clinical response and blood glucose monitoring.

Cat

Specific dosing information for cats is limited. Use cautiously and follow the same principles of starting at low doses and titrating carefully based on clinical response and blood glucose monitoring.

Warnings & Precautions

Diazoxide should be used with caution in dogs and cats due to its systemic effects on glucose regulation, fluid balance, and cardiovascular function. Careful patient selection and monitoring are essential to minimize adverse effects.

• Inappropriate use in certain hypoglycemic states: Contraindicated in functional hypoglycemia or hypoglycemia due to insulin overdose (e.g., diabetic patients), where it may worsen glycemic control.
• Hypersensitivity risk: Avoid use in patients with known hypersensitivity to thiazide diuretics due to structural similarity.
• Cardiac disease (CHF): May cause sodium and water retention, potentially exacerbating congestive heart failure; use cautiously and consider dose adjustment.
• Renal insufficiency: Reduced drug elimination may lead to accumulation and increased risk of adverse effects; dose adjustment and monitoring are recommended.
• Hepatic metabolism: As the drug is partially metabolized in the liver, adverse effects may be more pronounced in patients with hepatic disease.
• Fluid retention: Sodium and water retention may occur; monitor for signs such as edema or worsening cardiovascular status.
• Drug name confusion: Care should be taken to avoid confusion with similarly named drugs such as diazepam or diltiazem.

Drug Interactions

Diazoxide may interact with several medications that influence glucose regulation or cardiovascular function. These interactions can enhance hyperglycemic or hypotensive effects, requiring careful monitoring and dose adjustment when used concurrently.

• Glucocorticoids (e.g., dexamethasone, prednisolone): May enhance the hyperglycemic effects of diazoxide, increasing the risk of excessive blood glucose elevation.
• Phenothiazines (e.g., acepromazine, chlorpromazine): May potentiate the hyperglycemic effects of diazoxide.
• Thiazide diuretics: May increase the hyperglycemic effect of diazoxide; in some cases, used intentionally in combination, but with risk of hypotension.
• Other hypotensive agents (e.g., amlodipine, hydralazine, prazosin, telmisartan): Diazoxide may enhance their blood pressure–lowering effects, increasing risk of hypotension.
• Alpha-adrenergic agents (e.g., phenoxybenzamine): May reduce the effectiveness of diazoxide by altering glucose regulation.

Side Effects & Overdose

Side Effects

Adverse effects of diazoxide are primarily related to its effects on glucose metabolism, gastrointestinal tract, and fluid balance. Most effects are dose-dependent and may improve with dose adjustment or administration with food.

• Gastrointestinal signs: Anorexia, vomiting, and diarrhoea are the most common adverse effects.
• Hypersalivation: May occur, particularly in dogs, and can be associated with the drug’s bitter taste.
• Fluid retention: Sodium and water retention may lead to edema or worsening of cardiovascular disease.
• Tachycardia: May occur due to vasodilatory and systemic effects.
• Hematologic abnormalities: Including agranulocytosis, aplastic anemia, and thrombocytopenia (rare but serious).
• Pancreatitis: Reported in some cases.
• Hyperglycemia/diabetes mellitus: Excessive elevation of blood glucose may occur with higher doses or prolonged use.
• Cataracts: Reported with chronic use.

Overdose

Diazoxide overdose may result in significant metabolic disturbances, particularly severe hyperglycemia. Although relatively high oral doses have been tolerated in dogs, acute overdose still requires prompt recognition and supportive management.

• Severe hyperglycemia: Marked elevation in blood glucose levels is the primary concern.
• Ketoacidosis: May develop secondary to uncontrolled hyperglycemia.
• Management: Treatment includes administration of insulin, along with fluid and electrolyte therapy.
• Monitoring: Intensive and prolonged monitoring of glucose and clinical status is required.

Key Notes

Practical clinical points that help optimize the safe and effective use of diazoxide in dogs and cats in everyday veterinary practice:

• Adjunctive role: Commonly used when first-line therapies (dietary management and glucocorticoids) are insufficient to control hypoglycemia.
• Variable response: Clinical response can vary between patients, requiring individualized dose titration to achieve optimal control.
• Onset considerations: Effects on blood glucose may not be immediate; monitor trends rather than relying on single readings.
• Compounding considerations: May need to be compounded due to limited availability or cost, which can affect consistency and palatability.
• Administration challenges: Bitter taste may reduce compliance; alternative formulations or flavoring may improve acceptance.
• Long-term management: Often used as part of chronic medical management in patients where surgical or definitive treatment is not feasible.